Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs
Open Access
- 13 February 2006
- journal article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 8 (2) , R42
Abstract
Antimalarial agents have been widely used as disease-modifying antirheumatic drugs in the treatment of systemic lupus erythematosus (SLE) and other rheumatological diseases, although their mechanism of action has not yet been fully defined. It is known, however, that effective response to treatment is variable among patients. Thus, the identification of genetic predictors of treatment response would provide valuable information for therapeutic intervention. The aim of the present study was to analyze the effect of antimalarial treatment on tumor necrosis factor (TNF)α serum levels and evaluate the possible influence of TNFα and IL-10 functional genetic polymorphisms on the response to antimalarial drugs. To this end, TNFα serum levels were quantified in 171 SLE patients and 215 healthy controls by ELISA techniques and polymorphisms at positions -1,082 and -308 of the IL-10 and TNFα gene promoterswere determined by PCR amplification followed by hybridization with fluorescent-labeled allele-specific probes in 192 SLE patients and 343 matched controls. Data were related to clinical features and treatment at the time of sampling and during the course of the disease. Results showed a significantly higher amount of serum TNFα in the entire SLE population compared with controls. However, TNFα serum levels correlated negatively with the use of antimalarial treatment during at least three months before sampling. Patients under single or combined treatment with these drugs had TNFα serum levels similar to healthy controls, whereas untreated patients and those under corticosteroid or immunosuppressive therapies had increased amounts of this cytokine. This suggests, however, that antimalarial-mediated inhibition of TNFα was only significant in patients who were genetically high TNFα or low IL-10 producers. In addition, evaluation of SLE patients administered antimalarial drugs for three or more years who did not require any other specific SLE treatment indicates that patients with the combined genotype low IL-10/high TNFα are the best responders to antimalarial therapy, developing mild disease with a good course under this treatment. In conclusion, we proposed that an antimalarial-mediated downregulation of TNFα levels in SLE patients is influenced by polymorphisms at IL-10 and TNFα promoters. Our results may thus find important clinical application through the identification of patients who are the most likely to benefit from antimalarial therapy.Keywords
This publication has 34 references indexed in Scilit:
- Differential effect of IL10 and TNFα genotypes on determining susceptibility to discoid and systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2005
- Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a reviewAutoimmunity Reviews, 2005
- Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: An open‐label studyArthritis & Rheumatism, 2004
- The influence of genetic variation in the HLA–DRB1 and LTA–TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanerceptArthritis & Rheumatism, 2004
- Higher IL‐10 levels are associated with less effective clearance of Plasmodium falciparum parasitesParasite Immunology, 2004
- Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms1Transplantation, 2003
- New Indications for Treatment of Chronic Inflammation by TNF-α BlockadeThe American Journal of the Medical Sciences, 2003
- EFFECTS OF STIMULUS AND CELL TYPE ON THE EXPRESSION OF THE −308 TUMOUR NECROSIS FACTOR PROMOTER POLYMORPHISMCytokine, 2000
- A promoter polymorphism of tumor necrosis factor α associated with systemic lupus erythematosus in African‐AmericansArthritis & Rheumatism, 1997
- AN INVESTIGATION OF POLYMORPHISM IN THE INTERLEUKIN‐10 GENE PROMOTEREuropean Journal of Immunogenetics, 1997